Nature Communications (Nov 2020)
Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma
- Cinzia Federico,
- Kinan Alhallak,
- Jennifer Sun,
- Kathleen Duncan,
- Feda Azab,
- Gail P. Sudlow,
- Pilar de la Puente,
- Barbara Muz,
- Vaishali Kapoor,
- Luna Zhang,
- Fangzheng Yuan,
- Matea Markovic,
- Joseph Kotsybar,
- Katherine Wasden,
- Nicole Guenthner,
- Shannon Gurley,
- Justin King,
- Daniel Kohnen,
- Noha N. Salama,
- Dinesh Thotala,
- Dennis E. Hallahan,
- Ravi Vij,
- John F. DiPersio,
- Samuel Achilefu,
- Abdel Kareem Azab
Affiliations
- Cinzia Federico
- Department of Radiation Oncology, Washington University School of Medicine
- Kinan Alhallak
- Department of Radiation Oncology, Washington University School of Medicine
- Jennifer Sun
- Department of Radiation Oncology, Washington University School of Medicine
- Kathleen Duncan
- Department of Radiology, Washington University School of Medicine
- Feda Azab
- Department of Radiation Oncology, Washington University School of Medicine
- Gail P. Sudlow
- Department of Radiology, Washington University School of Medicine
- Pilar de la Puente
- Department of Radiation Oncology, Washington University School of Medicine
- Barbara Muz
- Department of Radiation Oncology, Washington University School of Medicine
- Vaishali Kapoor
- Department of Radiation Oncology, Washington University School of Medicine
- Luna Zhang
- Department of Radiation Oncology, Washington University School of Medicine
- Fangzheng Yuan
- Department of Radiation Oncology, Washington University School of Medicine
- Matea Markovic
- Department of Radiation Oncology, Washington University School of Medicine
- Joseph Kotsybar
- Department of Radiation Oncology, Washington University School of Medicine
- Katherine Wasden
- Department of Radiation Oncology, Washington University School of Medicine
- Nicole Guenthner
- Department of Radiation Oncology, Washington University School of Medicine
- Shannon Gurley
- Department of Radiation Oncology, Washington University School of Medicine
- Justin King
- Department of Medicine, Washington University School of Medicine
- Daniel Kohnen
- Department of Medicine, Washington University School of Medicine
- Noha N. Salama
- Department of Pharmaceutical and Administrative Sciences, St. Louis College of Pharmacy
- Dinesh Thotala
- Department of Radiation Oncology, Washington University School of Medicine
- Dennis E. Hallahan
- Department of Radiation Oncology, Washington University School of Medicine
- Ravi Vij
- Department of Medicine, Washington University School of Medicine
- John F. DiPersio
- Department of Medicine, Washington University School of Medicine
- Samuel Achilefu
- Department of Biomedical Engineering, Washington University
- Abdel Kareem Azab
- Department of Radiation Oncology, Washington University School of Medicine
- DOI
- https://doi.org/10.1038/s41467-020-19932-1
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 13
Abstract
The tumour microenvironment (TME) has a major role in chemoresistance in multiple myeloma. The authors show that a nanoparticle targeted to TME and loaded with bortezomib (BTZ) and Y27632 is more effective than free drugs, non-targeted and single-agent controls and reduces BTZ-related side effects.
